ReviewIndian journal of microbiology2025
HIV Cure: How Far We Have Come?
Review in Indian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bipolar CD4-targeted dual-DARPin-55/57 lipid nanoparticle enables efficient CRISPR/Cas-mediated HIV-1 DNA excision and reactivation blockade in latent CD4 T cell lines.Materials today. Bio · 2026Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Comparative Analysis of Virology and Pathogenesis of SARS-CoV-2 and HIV Infections: Implications for Public Health and Treatment Strategies.Infection and drug resistance · 2025Review
- HIV testing and diagnosis in 2021 at the apex tertiary referral hospital of India: Impact of COVID-19 pandemic continued.Indian journal of sexually transmitted diseases and AIDSArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Immunodeficiency Virus (HIV) is a major global healthcare burden. Current lifelong antiretroviral therapy drastically improves life expectancy but do not cure HIV. Therefore, at the existing growth rates, it is estimated that around 42 million people will be living with HIV by 2030 worldwide. A cure for HIV is need of the hour which could come in the form of remission (durable viral control without ART) or eradication (complete removal of latent replication-competent virus). In this review, we discuss recent advances in basic, applied and clinical aspects of latent HIV reservoirs including its tissue locations, cell types, cell properties, genomic integration sites and its significance, mechanism of reservoir seeding and methods to study the reservoirs. Natural models of functional cure which include elite controllers, viremic controllers, long term non-progressors and post-treatment controllers are discussed. Recent advances towards a functional HIV cure are discussed under headings; CCR5Δ32/Δ32 stem cells transplantation, shock and kill strategy, block and lock strategy, gene therapy and combined strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.